Lack of detection of human immunodeficiency virus type 1 in the saliva of infected children and adolescents.

OBJECTIVE To determine the prevalence of human immunodeficiency virus type 1 (HIV-1) in the saliva of infected children and adolescents. METHODS Saliva and blood samples were collected from 13 patients (age range, 1-15 years) with HIV-1 infection. Eleven were taking antiretroviral agents. The presence of HIV-1 was determined by polymerase chain reaction analysis of RNA and DNA as well as by viral culture of the saliva samples and by culture of peripheral blood mononuclear cells. RESULTS Although HIV-1 was cultured from peripheral blood mononuclear cells of 12 patients, it was not cultured from their saliva. Only 1 of 13 saliva samples yielded positive test results for HIV-1 RNA, and none did so for HIV-1 DNA. The specimen containing HIV-1 RNA was from an untreated 10-year-old asymptomatic boy with a CD4+ lymphocyte count of 0.91 x 10(9)/L (913 cells/microL) and no infectious virus detected in plasma. CONCLUSION The prevalence of HIV-1 in the saliva of HIV-1-infected children and adolescents is low and may not be infectious.

[1]  D. Dripps,et al.  Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. , 1995, The Journal of clinical investigation.

[2]  L. Epstein,et al.  Interaction of HIV-1 and human salivary mucins. , 1994, Journal of acquired immune deficiency syndromes.

[3]  S. Baron,et al.  HIV recovery from saliva before and after dental treatment: inhibitors may have critical role in viral inactivation. , 1993, Journal of the American Dental Association.

[4]  D. Cooper,et al.  Patients infected with human immunodeficiency virus type 1 have low levels of virus in saliva even in the presence of periodontal disease. , 1993, The Journal of infectious diseases.

[5]  J. Bremer,et al.  Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories , 1992, Journal of clinical microbiology.

[6]  R. Gatchel.  Dealing with Discomfort Managing Anxiety and Pain During Dental Treatment , 1992 .

[7]  C. Barr,et al.  Recovery of infectious HIV-1 from whole saliva. , 1992, Journal of the American Dental Association.

[8]  B. Prabhakar,et al.  Detection of proviral sequences in saliva of patients infected with human immunodeficiency virus type 1. , 1991, AIDS research and human retroviruses.

[9]  G. Cole,et al.  In vitro inhibition of HIV-1 infectivity by human salivas. , 1990, AIDS research and human retroviruses.

[10]  J. Levy,et al.  Human herpesvirus 6 inhibits human immunodeficiency virus type 1 replication in cell culture , 1990, Journal of clinical microbiology.

[11]  A. Collier,et al.  Plasma viremia in human immunodeficiency virus infection. , 1989, The New England journal of medicine.

[12]  P. Fox,et al.  Salivary inhibition of HIV-1 infectivity: functional properties and distribution in men, women, and children. , 1989, Journal of the American Dental Association.

[13]  P. Fox,et al.  Saliva inhibits HIV-1 infectivity. , 1988, Journal of the American Dental Association.

[14]  G. Friedland,et al.  Low occupational risk of human immunodeficiency virus infection among dental professionals. , 1988, The New England journal of medicine.

[15]  J. Gerberding,et al.  Risk of Transmitting the Human Immunodeficiency Virus, Cytomegalovirus, and Hepatitis B Virus to Health Care Workers Exposed to Patients With AIDS and AIDS-Related Conditions , 1987 .

[16]  J. Gerberding,et al.  Risk of transmitting the human immunodeficiency virus, cytomegalovirus, and hepatitis B virus to health care workers exposed to patients with AIDS and AIDS-related conditions. , 1987, The Journal of infectious diseases.

[17]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[18]  P. Fultz.  COMPONENTS OF SALIVA INACTIVATE HUMAN IMMUNODEFICIENCY VIRUS , 1986, The Lancet.

[19]  E. McCray.  Occupational risk of the acquired immunodeficiency syndrome among health care workers. , 1986, The New England journal of medicine.

[20]  B. Saltzman,et al.  Lack of transmission of HTLV-III/LAV infection to household contacts of patients with AIDS or AIDS-related complex with oral candidiasis , 1986 .

[21]  J. Jason,et al.  HTLV-III exposure during cardiopulmonary resuscitation. , 1985, The New England journal of medicine.

[22]  H. Masur,et al.  Retrovirus-Like Particles in Salivary Glands, Prostate and Testes of Aids Patients , 1985, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[23]  M. Gonda,et al.  HTLV-III in saliva of people with AIDS-related complex and healthy homosexual men at risk for AIDS. , 1984, Science.

[24]  P. Fox,et al.  Further studies of salivary inhibition of HIV-1 infectivity. , 1992, Journal of acquired immune deficiency syndromes.